/
PLUR
$2.15+$0.12 (+5.84%)prev close
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$21.9M
11M shares
52-week range
$1.99 – $5.96
4% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
1.35%
Moderate
Price (6 mo)
Loading chart…
Change$-5.61
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $50.0K | $54.0K | $23.0K | $0 | $234.0K | $287.0K | $326.0K | $1.3M |
| Cost of revenue | $2.0K | $2.0K | $1.6M | $1.4M | $1.1M | $9.0K | $4.0K | $682.0K |
| Gross profit | $48.0K | $52.0K | −$1.5M | −$1.4M | −$819.0K | $278.0K | $322.0K | $654.0K |
| Gross margin | 96.0% | 96.3% | -6726.1% | — | -350.0% | 96.9% | 98.8% | 49.0% |
| R&D | $22.6M | $24.6M | $20.1M | $30.1M | $24.4M | $15.7M | $12.4M | $12.9M |
| Operating income | −$33.7M | −$35.5M | −$29.5M | −$50.6M | −$41.6M | −$27.2M | −$22.2M | −$22.2M |
| EBITDA | −$24.1M | −$33.3M | −$27.4M | −$48.4M | −$39.4M | −$27.7M | −$20.2M | −$22.1M |
| Net income | −$26.1M | −$35.3M | −$29.2M | −$49.9M | −$41.2M | −$28.3M | −$20.9M | −$22.6M |
| Net margin | -52252.0% | -65383.3% | -126747.8% | — | -17624.8% | -9867.9% | -6407.4% | -1690.3% |
| EPS (diluted) | -19.74 | -23.20 | -12.80 | -14.19 | -10.24 | -6.18 | -3.99 | -3.56 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $3M | $-2.70 | $-2.70–$-2.70 | 1 |
| 2027 | $10M | $-1.90 | $-1.90–$-1.90 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Pluri Inc. Common Stock
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
www.pluri-biotech.com- Employees
- 142
- IPO / List date
- Oct 9, 1991
- HQ
- HAIFA
Held by traders on TradeandTell
No one on the platform currently holds PLUR.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 19,424 | $65.9K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-04-01 | 1-for-8reverse |
| 2019-07-25 | 1-for-10reverse |
Recent trades on TradeandTell
No one on the platform has traded PLUR yet.
